Cranberry (Vaccinium macrocarpon)
Of 2,271 on-market cranberry (vaccinium macrocarpon) products in the January 2026 DSLD dump, the median declared dose is 198 mg, and 46.4% list unspecified/undisclosed form as the primary form.
Form share
Of 2,267 products with an identifiable primary form, here is the share held by each form of Cranberry (Vaccinium macrocarpon) on the market today.
Embed this chart
Free to embed on your site or article — attribution and a link back are built into the frame.
| Form | Quality tier | n | Share |
|---|---|---|---|
| unspecified/undisclosed form | Unrated | 1,051 | 46.4% |
| Cranberry extract / concentrate (ratio or PAC-standardized) | Unrated | 689 | 30.4% |
| Cranberry whole-fruit powder | Unrated | 403 | 17.8% |
| Cranberry juice / juice powder / juice concentrate | Unrated | 124 | 5.5% |
Forms we recognize but found no primary-form products for in this release: Cranberry proanthocyanidins (PAC marker rows).
Form share over time
Entry-year breakdown of the top forms, 2012–2025.
Dose distribution
Deciles of declared dose per serving (mg), among 848 products with a disclosed amount.
Embed this chart
Free to embed on your site or article — attribution and a link back are built into the frame.
- 62.0% of products don't disclose an amount because Cranberry (Vaccinium macrocarpon) is declared inside a proprietary blend.
Where does your dose rank?
Enter a per-serving dose (mg) to see exactly how it compares to the 846 on-market cranberry (vaccinium macrocarpon) products with a disclosed amount. The chart above groups doses into deciles; this looks up the exact percentile for one number.
By dosage form
By target group
Top brands
Search interest over time
How often people search for cranberry (vaccinium macrocarpon) on Google, US only, the last 5 years. This is public interest, not DSLD label data — a spike here doesn't necessarily line up with anything on this page, and Google's own index (100 = that term's peak popularity in the chosen window) is relative, not an absolute search-volume count.
Or see this search directly on trends.google.com.
Forms explained
Label discloses only "Cranberry" with no powder, juice, concentrate or extract specified and no PAC content.
Whole-fruit powder is the least concentrated form; the UTI trials dose by PAC content and no verified study ranks powder against juice or concentrate at matched PAC.
No verified head-to-head comparison against other cranberry forms at matched PAC dose; NCCIH notes only that processing into tablets or capsules can reduce PAC concentration.
Source: https://www.nccih.nih.gov/health/cranberry (fetched; processing statement)
Typical standardization: Often a ratio (4:1 to 50:1) or a PAC percentage
The PAC-standardized extracts are what the dose-response UTI evidence is expressed in (PAC mg/day), but the labels' mg of extract cannot be converted to PAC mg without the declared PAC content, and no verified study ranks extract types.
Source: Xiong Z et al. 2024, Front Nutr 11:1422121, PMID 39668896; Babar A et al. 2021, BMC Urol 21(1):44, PMID 33757474
A row whose own name is the PAC is marker mass, not cranberry mass, and normally describes an extract row counted elsewhere; recorded without a dose.
Reference values
- RDA (adult): not established — Fruit used as a food/supplement; not an essential nutrient, no RDA/AI exists.
- Tolerable Upper Intake Level (adult): not established — Not established. NCCIH (https://www.nccih.nih.gov/health/cranberry, fetched) states oral cranberry is generally thought to be safe, that very large amounts can cause stomach upset and diarrhea (particularly in young children), and that evidence is conflicting on an interaction with warfarin. It gives no numeric upper limit.
- Studied clinical dose range: ?–? mg
- Deliberately left null. UTI-prevention trials dose cranberry by proanthocyanidin (PAC) content, not by product mass, so no mg-of-product range can be stated without inventing a conversion: Babar A et al. 2021, BMC Urol 21(1):44, PMID 33757474 -- double-blind RCT (n=145 women with recurrent UTI), standardized cranberry PAC extract 2 x 18.5 mg PAC/day vs 2 x 1 mg for 24 weeks; no significant reduction in symptomatic UTIs (high vs low dose). Xiong Z et al. 2024, Front Nutr 11:1422121, PMID 39668896 -- meta-analysis of 10 RCTs; daily PAC intake of at least 36 mg was associated with an 18% lower UTI risk (RR 0.82, 95% CI 0.69-0.98), while intake below 36 mg showed no significant reduction. Because most labels declare the mass of juice powder, concentrate or extract rather than PAC content, label rows cannot be compared with these PAC doses.
- Note: Unit basis: mg of cranberry material as declared (juice powder, whole-fruit powder, concentrate or "25:1/50:1" extract), which are not interchangeable. NCCIH (fetched) notes that processing cranberries into tablets or capsules can reduce PAC concentration, and that since 2020 the FDA has allowed a "limited evidence" qualified claim for cranberry supplements and recurrent UTI risk in healthy women. The generic row "Proanthocyanidins" is NOT an alias: it is mostly grape-seed, pine-bark or red-wine PACs. "Mountain Cranberry" (lingonberry), "High Bush Cranberry", cranberry seed/seed oil/seed protein and cranberry leaf are different materials and are deliberately not aliased (a dry run confirmed they stay unmatched).